Hansoh Pharma is a leading innovation-driven pharmaceutical company in China, with the mission of "Continuous innovation for better life". The Company focuses on major disease therapeutic areas including oncology, anti-infections, central nervous system, metabolism and autoimmunity. Consistently ranked among the Top 100 Global Pharmaceutical Enterprises and the Top 3 China's Best Industrial Enterprises in Pharmaceutical R&D Pipeline, we are recognized as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. The Company was listed on the Hong Kong Stock Exchange in June 2019 (03692.HK).
Hansoh Pharma actively explores the cutting edge of global pharmaceutical technology, accelerating the R&D and commercialization of innovative products. Currently, the Company has established four R&D centers in Shanghai, Lianyungang, Changzhou, and Maryland (USA), with over 2,300 professional R&D personnel. The Company has built a comprehensive R&D system covering the entire process from frontier information collection, compound design and screening, pharmacological and toxicological research, to clinical medical research. The Company has founded multiple national-level R&D institutions, including the National Enterprise Technology Center, Post-doctoral Research Station, and Key National Laboratory. Through years of accumulation, the Company has developed high-efficiency innovative drug R&D capabilities, covering antibody-drug conjugates (ADC), synthetic peptides, siRNA, bispecific antibodies, and small molecules. The Company had more than 70 clinical trials of innovative drugs being investigated, covering more than 40 innovative drug candidates, and has cultivated a robust and highly competitive R&D pipeline.
In 2025, Hansoh Pharma recorded revenue of RMB15,028 million, representing a year-on-year increase of 22.6%. Revenue of innovative drugs and collaborative products reached RMB12,354 million, and the proportion of total revenue has increased to 82.2%. Innovative drugs have become the core driver of the Company's sustainable growth. As of the end of the Reporting Period, The Company has had 7 innovative drugs generating sales revenue in China, with eleven indications included in China's National Reimbursement Drug List (NRDL), providing more patients high-quality treatments while significantly reducing their medication costs.
Under its global strategy, Hansoh Pharma has accelerated business development (BD) collaborations, actively exploring novel targets, expanding new directions, and partnering on new technologies. To date, the company has entered into out-licensing collaborations with internationally leading pharmaceutical enterprises such as GSK, MSD, Regeneron and Roche, striving to bring its self-developed results to the global market.
In terms of sustainable development, we have deeply integrated ESG principles with the Company’s long-term strategy. Hansoh Pharma has been awarded the highest AAA rating in the MSCI ESG Assessment. In the S&P Global Corporate Sustainability Assessment, Hansoh Pharma has been ranked first in the Chinese pharmaceutical industry for consecutive years.
Hansoh Pharma has always maintained dynamic consistency with global advanced levels of creation by continuously designing and building production facilities and production lines in accordance with international advanced quality standards. The Company’s production quality system has been officially certified by FDA in the United States, EMA of the European Union, and PMDA in Japan, and its key preparations and active pharmaceutical ingredients (APIs) have been approved for marketing in Europe, America, Japan, etc.
Innovation drives growth, and technology shapes the future. Hansoh Pharma will continue to deepen its dual-engine strategy of "Innovation and Globalization", with a view to meeting the clinical needs of patients in China and around the world, and contributing to exploring and developing more innovative and effective medicines to safeguard life and health.
